LJPC - La Jolla Pharmaceutical Company
| Previous Close | 30.29 |
| Open | 30.28 |
| Bid | 29.90 x 100 |
| Ask | 30.95 x 200 |
| Day's Range | 30.16 - 31.06 |
| 52 Week Range | 22.68 - 41.36 |
| Volume | 338,187 |
| Avg. Volume | 560,082 |
| Market Cap | 803.209M |
| Beta | 2.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.41 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.50 |
- Barrons.com•23 days ago
[$$] 3 Biotech Stocks a Pro Is Buying Now
The last time we checked in with Joseph Edelman, the founder, chief executive and portfolio manager of Perceptive Advisors and its hedge fund, Perceptive Life Sciences, he was buying stocks ahead of the new year. Edelman famously oversaw a 4% gain in 2016 as the biotech sector tumbled 20%. What stocks are Edelman, and his chief investment officer, Adam Stone, buying now?
- GlobeNewswire•last month
Market Trends Toward New Normal in La Jolla Pharmaceutical, AquaVenture, Duluth, Community Bank System, Cubic, and TrustCo Bank Corp NY — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, March 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•last month
La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States
SAN DIEGO, March 22, 2018-- La Jolla Pharmaceutical Company today announced that GIAPREZA™, injection for intravenous infusion, is now commercially available. In December 2017, GIAPREZA was approved by ...
- GlobeNewswire•last month
La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
SAN DIEGO, March 15, 2018-- La Jolla Pharmaceutical Company, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, ...
- GlobeNewswire•last month
La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock
SAN DIEGO, March 14, 2018-- La Jolla Pharmaceutical Company, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, ...
- GlobeNewswire•2 months ago
GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury
Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on Advances in Critical Care Nephrology AKI & CRRT 2018. Manuscript Published Online in Critical Care Medicine. ...
- GlobeNewswire•2 months ago
GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study
SAN DIEGO, Feb. 25, 2018-- La Jolla Pharmaceutical Company today announced that an abstract, entitled“ Effect of Disease Severity on Survival in Patients Receiving Angiotensin II for Vasodilatory Shock,” ...
- Associated Press•2 months ago
La Jolla Pharmaceutical posts 4Q loss
On a per-share basis, the San Diego-based company said it had a loss of $1.74. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•2 months ago
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
SAN DIEGO, Calif., Feb. 22, 2018-- La Jolla Pharmaceutical Company, a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening ...
- GlobeNewswire•2 months ago
La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study
SAN DIEGO, Feb. 21, 2018-- La Jolla Pharmaceutical Company today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’ s open-label study of GIAPREZA TM, injection for intravenous ...
- Motley Fool•2 months ago
Why Lumber Liquidators Holdings, Stamps.com, and La Jolla Pharmaceutical Slumped Today
The market soared, but these stocks got left behind. Find out why.
- Benzinga•2 months ago
Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug
In the absence of a potential buyout, the downside risk for La Jolla Pharmaceutical Company (NASDAQ: LJPC ) is greater than the upside potential in the next two to three years, according to Jefferies. ...
- Simply Wall St.•3 months ago
What You Must Know About La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) Financial Health
La Jolla Pharmaceutical Company (NASDAQ:LJPC), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off isRead More...
- GlobeNewswire•3 months ago
Consolidated Research: 2018 Summary Expectations for Freshpet, eHealth, SEACOR, La Jolla Pharmaceutical, Rogers, and On Assignment — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Freshpet, ...
- Investor's Business Daily•4 months ago
La Jolla Pharmaceutical Hits 80-Plus Relative Strength Rating Benchmark
La Jolla Pharmaceutical sees its Relative Strength Rating reach the 80-plus level.
- Motley Fool•4 months ago
3 Biotechs Launching Their First Commercial Drugs in 2018
New drugs with multibillion-dollar market opportunities will hit pharmacy shelves in 2018.
Capital Cube•4 months agoLa Jolla Pharmaceutical Co. is trading above its 50 day moving average : LJPC-US : December 28, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for La Jolla Pharmaceutical Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
- Zacks•4 months ago
La Jolla Pharmaceutical (LJPC) Surges: Stock Moves 11.1% Higher
The shares of La Jolla Pharmaceutical (LJPC) rose 11.1% on Friday
- Investor's Business Daily•4 months ago
Christmas Comes Early For These 5 Biotechnology Stocks
Biotech stocks rallied on Friday amid a strategic acquisition by Swiss drug maker Roche and regulatory approvals.
- GuruFocus.com•4 months ago
What the Latest Approval Means for La Jolla Pharmaceutical
A look at the latest regulatory approval in the US
- Motley Fool•4 months ago
Here's Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher Today
The FDA surprised the biopharmaceutical with good news today.
- Reuters•4 months ago
FDA approves La Jolla's low blood pressure drug
La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure. The company said it plans to make Giapreza available for patients in the United States in March. La Jolla's shares rose 4.2 percent to $32.45 in extended trading on Thursday.
- Benzinga•4 months ago
Analyst: La Jolla Pharma A Buy Ahead Of February FDA Date
La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has an upcoming catalyst in the form of a Feb. 28 PDUFA date. An analyst at H.C. Wainwright recommends buying of the shares ahead of the decision. The Analyst ...
